未经评估:2019年冠状病毒病(COVID-19),由严重急性呼吸综合征冠状病毒2(SARS-CoV-2)引起,是全球范围内的主要医疗保健威胁。自2021年11月首次发现SARS-CoV-2的Omicron(B.1.1.529)变体以来,它已演变为多个谱系,包括BA.1、BA.2-BA.4和BA.5。SARS-CoV-2变体可能会增加传播性,致病性,以及对疫苗诱导的免疫力的抗性。因此,使用变异表型对循环谱系进行流行病学监测至关重要.本研究的目的是表征住院COVID-19患者中OmicronBA.2感染的临床结局,并对此类病例进行SARS-CoV-2的免疫学评估。
UNASSIGNED:我们评估了BioICSARS-CoV-2免疫球蛋白(Ig)M/IgG检测试剂盒的分析和临床表现,用于检测257例感染Omicron变体的SARS-CoV-2抗体。
未经证实:38例患者预后不良,包括8例以合并症为特征的患者死亡,这些患者易患严重的COVID-19。关注变体(VOC)分型和血清学分析确定了台湾第四波爆发中出现的BA.2变体的时间依赖性流行趋势。在分析的257个标本中,108(42%)和24(9.3%)分别为抗NIgM和IgG阳性。
未经评估:这些样本的VOC分型允许按时间间隔识别流行趋势,包括替换B.1.1.529变体的B.1.617.2变体。此外,抗体检测可能是COVID-19诊断的补充方法。血清学检测结果与逆转录-聚合酶链反应循环阈值相结合对疾病预后具有潜在价值,从而帮助临床医生或医疗保健部门进行流行病调查。
Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is a major healthcare threat worldwide. Since it was first identified in November 2021, the Omicron (B.1.1.529) variant of SARS-CoV-2 has evolved into several lineages, including BA.1, BA.2-BA.4, and BA.5. SARS-CoV-2 variants might increase transmissibility, pathogenicity, and resistance to vaccine-induced immunity. Thus, the epidemiological surveillance of circulating lineages using variant phenotyping is essential. The aim of the current study was to characterize the clinical outcome of Omicron BA.2 infections among hospitalized COVID-19 patients and to perform an immunological assessment of such cases against SARS-CoV-2.
We evaluated the analytical and clinical performance of the BioIC SARS-CoV-2 immunoglobulin (Ig)M/IgG detection kit, which was used for detecting antibodies against SARS-CoV-2 in 257 patients infected with the Omicron variant.
Poor prognosis was noted in 38 patients, including eight deaths in patients characterized by comorbidities predisposing them to severe COVID-19. The variant-of-concern (VOC) typing and serological analysis identified time-dependent epidemic trends of BA.2 variants emerging in the outbreak of the fourth wave in Taiwan. Of the 257 specimens analyzed, 108 (42%) and 24 (9.3%) were positive for anti-N IgM and IgG respectively.
The VOC typing of these samples allowed for the identification of epidemic trends by time intervals, including the B.1.1.529 variant replacing the B.1.617.2 variant. Moreover, antibody testing might serve as a complementary method for COVID-19 diagnosis. The combination of serological testing results with the reverse transcription-polymerase chain reaction cycle threshold value has potential value in disease prognosis, thereby aiding in epidemic investigations conducted by clinicians or the healthcare department.